PharmacoEconomics

Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations
pp. 713-726(14)
Authors: Prosser, Lisa A.; Hammitt, James K.; Keren, Ron

The Increasingly Complex Fourth Hurdle for Pharmaceuticals
pp. 727-734(8)
Authors: Cohen, Joshua; Stolk, Elly; Niezen, Maartje

Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis
pp. 735-750(16)
Author: Green, Colin

Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and Analysis of the Literature
pp. 751-768(18)
Author: Shorr, Andrew F.

Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
pp. 769-782(14)
Authors: Heeg, Bart M.S.; Peters, Ron J.G.; Botteman, Marc; van Hout, Ben A.

Preferences of Community Pharmacists for Extended Roles in Primary Care: A Survey and Discrete Choice Experiment
pp. 783-792(10)
Authors: Scott, Anthony; Bond, Christine; Inch, Jackie; Grant, Aileen

Reliability of Medicaid Claims Versus Medical Record Data: In a Cost Analysis of Palivizumab
pp. 793-800(8)
Authors: Julie Jacobson Vann,; Feaganes, John; Wegner, Steven

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
pp. 801-802(2)
Authors: Home, Philip; Bagust, Adrian; Taylor, Matthew; Ambery, Philip; Samara Mendes da Costa,

The Authors' Reply
pp. 802-805(4)
Authors: Tilden, Dominic P.; Mariz, Segundo; O'Bryan-Tear, Gillies; Bottomley, Julia; Diamantopoulos, Alexander